Idiopathic calcium oxalate urolithiasis and endogenous oxalate production

Critical Reviews in Clinical Laboratory Sciences

Volumn 33, Issue 1, 1996, Pages 39-82

  Baker, Paul W ^a   Rofe, Allan M ^a   Bais, Renze ^a,b  

^a INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Calcium; Cysteine glyoxylate adduct; Glycolate; Glyoxylate; Oxalate; Thiazolidine 2,4 dicarboxylate; Thiols; Urolithiasis

Indexed keywords

AMINOTHIOL; CALCIUM; CITRIC ACID; GLYCOSAMINOGLYCAN; GLYOXYLIC ACID; HYDROXY ACID OXIDASE A; LACTATE DEHYDROGENASE; MAGNESIUM; OXALIC ACID; PYROPHOSPHATE; URATE;

CALCIUM EXCRETION; CALCIUM OXALATE STONE; ENZYME INHIBITION; FLUID THERAPY; HUMAN; LITHOTRIPSY; MAGNESIUM EXCRETION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; URIC ACID URINE LEVEL; URINARY EXCRETION; URINE VOLUME;

EID: 0030034813     PISSN: 10408363     EISSN: None     Source Type: Journal    
DOI: 10.3109/10408369609101486     Document Type: Review

References (274)

1. Michell AR. Urolithiasis-historical, comparative and pathophysiological aspects: A review. J R Soc Med 1989; 82: 669-72.
2. Van Aswegen CH, Du Plessis DJ. A biochemical approach to renal stone formation. Adv Clin Chem 1992; 29: 263-72.
3. Menon M, Koul H. Clinical review 32: Calcium oxalate nephrolithiasis. J Clin Endocrinol Metab 1992; 74: 703-7.
4. Robertson WG. Urinary tract calculi. In: Nordin BEC, Need AG, Morris HA, eds. Metabolic bone and stone disease. Pp. 249-310. London: Churchill Livingston, 1993.
5. Smith LH. The medical aspects of urolithiasis: an overview. J Urol 1989; 141: 707-10.
6. Watts RWE. Renal calculi and metabolic disorders of the kidney. In: Weatherall DJ, Ledingham JGG, Warrell DA, eds. Oxford textbook of medicine. Pp. 18.81-18.87. Oxford: Oxford University Press, 1983.
7. Curhan GC, Willett WC, Rimm EB, et al. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med 1993; 328: 833-8.
8. Asper R. Epidemiology and socioeconomic aspects of urolithiasis. Urol Res 1984; 2: 1-5.
9. Robertson WG. Urinary tract calculi. In: Nordin BEC, ed. Metabolic bone and stone disease. Pp. 271-326. Hong Kong: Churchill Livingstone, 1984.
10. Baker PW, Coyle P, Bais R, et al. Influence of season, age, and sex on renal stone formation in South Australia. Med J Aust 1993; 159: 390-2.
11. Coe FL, Favus MJ. Nephrolithiasis. In: Brennor BM, Rector FC, eds. The kidney. Pp. 1728-67. Philadelphia: W. B. Saunders Company, 1991.
12. Smith LH, Wilson DM, Goldfarb S, et al. Renal stones, Endocrinol Metab Clin North Am 1990; 19: 773-947.
13. Pyrah LN. ed. Renal calculus. Berlin: Springer-Verlag, 1979.
14. Su CJ, Shevock PN, Khan SR, et al. Effect of magnesium on calcium oxalate urolithiasis. J Urol 1991; 145: 1092-5.
15. Rofe AM, Bais R Conyers RAJ. The effect of dietary refined sugars and sugar alcohols on renal calcium oxalate deposition in ethylene glycol-treated rats. Food Chem Toxicol 1986; 24: 397-403.
16. Khan SR. Pathogenesis of oxalate urolithiasis: Lessons from experimental studies with rats. Am J Kidney Dis 1991; 17: 398-401.
17. Welshman SG, McGeowin MG. Urinary citrate excretion in stone-formers and normal controls. Br J Urol 1976; 48: 7-11.
18. Wong SYP, Slater SR, Evans RA, et al. Metabolic studies in kidney stone disease. Q J Med 1992; 299: 247-58.
19. Grases F, Conte A, Genestar C, et al. Inhibitors of calcium oxalate crystallization and urolithiasis. Urol Int 1992; 48: 409-14.
20. Grover PK, Ryall RL Marshall VR. Effect of urate on calcium oxalate crystallization in human urine: Evidence for a promotory role of hyperuricosuria in urolithiasis. Clin Sci 1990; 79: 9-15.
21. Coe FL, Lawton RL, Goldstein RB, et al. Sodium urate accelerates precipitation of calcium oxalate in vitro. Proc Soc Exp Biol Med 1975; 149: 926-9.
22. Smith LH. Idiopathic calcium oxalate urolithiasis. Endocrinol Metab Clin North Am 1990; 19: 937-47.
23. Pak CYC, Skurla C Harvey J. Graphic display of urinary risk factors for renal stone formation. J Urol 1985; 134: 867-70.
24. Coe FL, Favus MJ. Disorders of bone and mineral metabolism. New York: Raven Press, 1992.
25. Finlayson B. Physicochemical aspects of urolithiasis. Kidney Int 1978; 13: 344-60.
26. Fleisch H. Inhibitors and promotors of stone formation. Kidney Int 1978; 13: 361-71.
27. Bateson EM. Renal calculi and climate. Med J Aust 1973; 2: 111-3.
28. Robertson WG, Gallagher JC, Marchall DH, et al. Seasonal variation in urinary excretion of calcium. Br Med J 1974; 4: 436-7.
29. Borghi L, Meschi T, Amato F, et al. Hot occupation and nephrolithiasis. J Urol 1993; 150: 1757-60.
30. Finlayson B. Renal lithiasis in review. Urol Clin North Am 1974; 1: 181-212.
31. Ackermann D. Prophylaxis in idiopathic calcium urolithiasis. Urol Res 1990; 18: S37-40.
32. Pak CYC, Sakhaee K, Crowther C, et al. Evidence justifying a high fluid intake in treatment on nephrolithiasis. Ann Intern Med 1980; 93: 36-9.
33. Cupisti A, Morelli E, Lupetti S, et al. Low urine citrate excretion as main risk factor for recurrent calcium oxalate nephrolithiasis in males. Nephron 1992; 61: 73-6.
34. Nicar MJ, Skurla C, Sakhaee K, et al. Low urinary citrate excretion in nephrolithiasis. Urology 1983; 21: 8-14.
35. Johansson G, Backman U, Danielson BG, et al. Magnesium metabolism in renal stone formers. Effects of therapy with magnesium hydroxide. Scand J Urol Nephrol 1980; 53: 125-30.
36. Tiselius HG. Oxalate and renal stone formation. Scand J Urol Nephrol 1980; 53: 135-46.
37. Edwards P, Nemat S Rose GA. Effects of oral pyridoxine upon plasma and 24-hour urinary oxalate levels in normal subjects and stone formers with idiopathic hypercalciuria. Urol Res 1990; 18: 393-6.
38. Lucke H, Stange G Murer H. Sulphate-ion/sodium-ion co-transport by brush-border membrane vesicles isolated from rat kidney cortex. Biochem J 1979; 182: 223-9.
39. Harris KS, Richardson KE. Glycolate in the diet and its conversion to urinary oxalate in the rat. Invest Urol 1980; 18: 106-9.
40. Balcke P, Zazgornik J, Sunder-Plassmann G, et al. Transient hyperoxaluria after ingestion of chocolate as a high risk factor for calcium oxalate calculi. Nephron 1989; 51: 32-4.
41. Laker MF. The clinical chemistry of oxalate metabolism. Adv Clin Chem 1983; 23: 259-97.
42. Williams AW, Wilson DM. Dietary intake, absorption, metabolism, and excretion of oxalate. Semin Nephrol 1990; 10: 2-8.
43. Conyers RAJ. Ascorbic acid intake, renal function, and urinary oxalate excretion. Aust NZ J Med 1985; 15: 353-5.
44. Gambardella RL, Richardson KE. The pathways of oxalate formation from phenylalanine, tyrosine, tryptophan and ascorbic acid in the rat. Biochim Biophys Acta 1977; 499: 156-68.
45. Urivetzky M, Kessaris D Smith AD. Ascorbic acid overdosing: a risk factor for calcium oxalate nephrolithiasis. J Urol 1992; 147: 1215-8.
46. Winek CL, Shingleton DP Shanor SP. Ethylene and diethylene glycol toxicity. Clin Toxicol 1978; 13: 297-324.
47. 14C-labelled ethylene glycol. Biochem J 1961; 79: 482-9.
48. Thomas DW, Hannett B, Chalmers A, et al. Oxalate excretion during carbohydrate infusions. Int J Vitam Res 1976; 15: 181-92.
49. Hannett B, Thomas DW, Chalmers AH, et al. Formation of oxalate in pyridoxine or thiamine deficient rats during intravenous xylitol infusion. J Nutr 1976; 107: 458-65.
50. Rofe AM, Thomas DW, Edwards RG, et al. Oxalate synthesis from xylitol: In vivo and in vitro studies. Biochem Med 1977; 18: 440-51.
51. Rofe AM, Conyers RAJ Edwards JB. Oxalate excretion in rats injected with xylitol or glycolate: stimulated by phenobarbitone pre-treatment. AJEBAK 1979; 57: 171-6.
52. 14C carbohydrates in isolated rat hepatocytes. AJEBAK 1980; 58: 103-16.
53. James HM, Bais R, Edwards JB, et al. Models for the metabolic production of oxalate from xylitol in humans: A role of fructokinase and aldolase. AJEBAK 1982; 60: 117-22.
54. James HM, Williams SG, Bais R, et al. The metabolic production of oxalate from xylitol: activity of transketolase, transaldolase, fructokinase and aldolase in liver, kidney, brain, heart and muscle in rat, mouse, guinea pig, rabbit and human. Int J Vitam Res 1985; 29: 29-46.
55. Bais R, James HM, Rofe AM, et al. The purification and properties of human liver ketohexokinase. A role for ketohexokinase and fructose-biphosphate aldolase in the metabolic production of oxalate from xylitol. Biochem J 1985; 230: 53-60.
56. Erickson SB, Cooper K, Broadus AE, et al. Oxalate absorption and postprandial urine super-saturation in an experimental human model of absorptive hypercalciuria. Clin Sci 1984; 67: 131-8.
57. Robertson WG, Peacock M. The cause of idiopathic calcium stone disease: Hypercalciuria or hyperoxaluria. Nephron 1980; 26: 105-10.
58. Marshall RW, Cockran M Hodgkinson A. Relationship between calcium and oxalic acid intake in the diet and their excretion in the urine of normal and renal-stone forming subjects. Clin Sci 1972; 43: 91-9.
59. Brinkley L, McGuire J, Gregory J, et al. Bioavailability of oxalate in foods. Urology 1981; 17: 534-8.
60. Berg W, Bother C Pirlich W. Influence of magnesium on the absorption and excretion of calcium and oxalate ions. Eur Urol 1986; 12: 274-82.
61. Hodgkinson A. Evidence of increased oxalate absorption in patients with calcium-containing renal stones. Clin Sci 1978; 54: 291-4.
62. Nakada T, Sasagawa I, Furuta K, et al. Effect of high calcium on urinary oxalate excretion in urinary stone formers. Eur Urol 1988; 15: 264-70.
63. Brown WW, Wolfson M. Diet as culprit or therapy. Med Clin North Am 1993; 77: 783-94.
64. Smith LH. Diet and hyperoxaluria in the syndrome of idiopathic calcium oxalate urolithiasis. Am J Kidney Dis 1991; 17: 370-5.
65. Rao PN, Prendville V, Buxton A, et al. Dietary management of urinary risk factors in renal stone formers. Br J Urol 1982; 54: 578-83.
66. Baggio B, Marchini F, Gambaro G, et al. Raised transmembrane oxalate flux in red blood cells in idiopathic calcium oxalate nephrolithiasis. Lancet 1984; 12-3.
67. Baggio B, Gambaro G, Marchini F, et al. An inheritable anomaly of red-cell oxalate transport in "primary" calcium nephrolithiasis correctable with diuretics. N Engl J Med 1986; 314: 599-604.
68. Gambaro G, Baggio B. Idiopathic calcium oxalate nephrolithiasis: A cellular disease. Scanning Microsc 1992; 6: 247-54.
69. Baggio B, Gambaro G, Borsatti A, et al. Relation between band-3 red blood cell protein and transmembrane oxalate flux in stone formers. Lancet 1984; 223-4.
70. Baggio B, Marzaro G, Gambaro G, et al. Glycosaminoglycan content, oxalate self-exchange and protein phosphorylation in erythrocytes of patients with "idiopathic" calcium oxalate nephrolithiasis. Clin Sci 1990; 79: 113-6.
71. Baggio B, Gambaro G, Marzaro G, et al. Effects of the oral administration of glycosaminoglycans on cellular abnormalities associated with idiopathic calcium oxalate nephrolithiasis. Eur J Clin Pharmacol 1991; 40: 237-40.
72. Borsatti A. Calcium oxalate nephrolithiasis: defective oxalate transport. Kidney Int 1991; 39: 1283-98.
73. Baggio B, Gambaro G, Marchini F, et al. Correction of erythrocyte abnormalities in idiopathic calcium-oxalate nephrolithiasis and reduction of urinary oxalate by oral glycosaminoglycans. Lancet 1991; 338: 403-5.
74. Gill HS, Rose A. Mild metabolic hyperoxaluria and its response to pyridoxine. Urol Int 1986; 41: 393-6.
75. Khan SR, Shevock PN Hackett RL. Magnesium oxide administration and prevention of calcium oxalate nephrolithiasis. J Urol 1993; 149: 412-6.
76. Bais R, Rofe AM Conyers RAJ. Investigations into the effect of glyoxylate decarboxylation and transamination on oxalate formation in the rat. Nephron 1991; 57: 460-9.
77. Bowyer RC, Brockis JG McCulloch RK. Glycosaminoglycans as inhibitors of calcium oxalate crystal growth and aggregation. Clin Chim Acta 1979; 95: 23-8.
78. Fleisch H, Bisaz S. Isolation from urine of pyrophosphate a calcification inhibitor. Am J Physiol 1962; 203: 671-5.
79. Meyer JL, Smith LH. Growth of calcium oxalate crystals. II. Inhibition by natural urinary crystal growth inhibitors. Invest Urol 1975; 13: 36-9.
80. Kitamura T, Zerwekh JE Pak CYC. Partial biochemical and physicochemical characterisation of organic macromolecules in urine from patients with renal stones and control subjects. Kidney Int 1982; 21: 379-86.
81. Zerwekh JE, Holt K Pak CYC. Natural urinary macromolecular inhibitors: Attenuation of inhibitory activity by urate salts. Kidney Int 1983; 23: 838-41.
82. Shorr E, Bernheim AR Taussky H. The relation of uric acid excretion to the menstrual cycle and the steroidal reproductive hormones. Science 1942; 95: 606-7.
83. Abdulhadi MH, Hall PM Streem SB. Can citrate therapy prevent nephrolithiasis? Urology 1993; 41: 221-4.
84. Barcelo P, Servitge E, Rousaud A, et al. Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol 1993; 150: 1761-4.
85. Tawashi R, Cousineau M Denis G. Calcium oxalate crystal growth in normal urine: Role of contraceptive hormones. Urol Res 1984; 12: 7-9.
86. Pak CYC, Koenig K, Khan R, et al. Physicochemical action of potassium-magnesium citrate in nephrolithiasis. J Bone Miner Res 1992; 7: 281-5.
87. Herrmann U, Schwille PO, Schwarzlaender H, et al. Citrate and recurrent idiopathic calcium urolithiasis. A longitudinal pilot study on the metabolic effects of oral potassium sodium citrate administered as short-, medium- and long-term to male stone patients. Urol Res 1992; 20: 347-53.
88. Drach GW, Springman K, Gottung B, et al. Effect of human urine on the aggregation of calcium oxalate crystals: Normal persons versus stone-formers. In: Urolithiasis and related clinical research, proceedings of the 5th international conference on urolithiasis. Pp. 875-878. New York: Plenum Press, 1985.
89. Kok DJ, Papapoulos SE Bijvoet OLM. Excessive crystal agglomeration with low citrate excretion in recurrent stone-formers. Lancet 1986; 1056-8.
90. Smith LH, Werness PG, Lee KE, et al. Inhibitors of crystal growth and aggregation in calcium urolithiasis. Clin Res 1979; 26: 727a.
91. Dent CE, Sutor DJ. Presence or absence of inhibitor of calcium-oxalate crystal growth in urine of normals and of stone-formers. Lancet 1971; ii: 775-8.
92. Conte AC, Roca P, Genestar C, et al. Uric acid and its relationship with glycosaminoglycans in normal and stone-former subjects. Nephron 1989; 52: 162-5.
93. Grases F, Conte A, Coll R, et al. The role of hyperoxaluria in the formation of calcium oxalate urinary calculi, and its association with other biochemical measurements. Scand J Urol Nephrol 1990; 24: 211-3.
94. Grases F, Genestar C, March P, et al. Variations in the activity of urinary inhibitors in calcium oxalate urolithiasis. Br J Urol 1988; 62: 515-20.
95. Grases F, Genestar C, Conte A, et al. Inhibitory effect of pyrophosphate, citrate, magnesium and chondroitin sulphate in calcium oxalate urolithiasis. Br J Urol 1989; 64: 235-7.
96. Barilla DE, Notz C, Kennedy D, et al. Renal oxalate excretion following oral oxalate loads in patients with ileal disease and with renal and absorptive hypercalciurias: effect of calcium and magnesium. Am J Med 1978; 64: 576-85.
97. Hammerstein G. Calcium oxalate and its solubility in the presence of inorganic salts, with special reference to the occurrence of oxalate. CR Lab Carlsberg 1929; 17: 83.
98. Kohri K, Garside J Blacklock NJ. The role of magnesium in calcium oxalate urolithiasis. Br J Urol 1988; 61: 107-12.
99. Li MK, Blacklock NJ Garside J. Effect of magnesium on calcium oxalate crystallization. J Urol 1985; 133: 123-8.
100. Ryall RL, Harnett RH Marshall VR. The effect of urine, pyrophosphate, citrate, magnesium and glycosaminoglycans on the aggregation of calcium oxalate crystals in vitro. Clin Chim Acta 1981; 112: 349-56.
101. Geigy Scientific Tables 1981.
102. Batielle P, Pruna A, Leflon P, et al. Evidence for magnesium depletion in idiopathic hypercalciuria. In: Urolithiasis and related clinical research, proceedings of the 5th international conference on urolithiasis. Pp. 323-6. New York: Plenum Press, 1985.
103. Drach GW, Gaines J Donovan J. Magnesium metabolism related to calcium urolithiasis? In: Urolithiasis and related clinical research, proceedings of the 5th international conference on urolithiasis. Pp. 241-4. New York: Plenum Press, 1985.
104. 2 plus Cu,Zn-super-oxide dismutase reflects the activity of free copper released from the oxidatively damaged enzyme. J Biol Chem 1992; 267: 25371-7.
105. Tiselius HG, Larsson L. Studies on urine composition in patients with calcium oxalate stone disease. In: Urolithiasis and related clinical research, proceedings of the 5th international conference on urolithiasis. Pp. 291-4. New York: Plenum Press, 1985.
106. Pak CYC, Nicar MJ Northcutt C. The definition of the mechanism of hypercalciuria is necessary for the treatment of recurrent stone formers. In: Contributions to nephrology. Basel: S. Karger, 1982.
107. Pak CYC. Kidney stones: pathogenesis, diagnosis and therapy. In: Metabolic bone disease and clinically related disorders. Philadelphia: W. B. Saunders Company, 1990.
108. +-citrate. Nephron 1993; 65: 578-82.
109. Bisaz S, Felix R, Neuman W, et al. Quantitative determination of inhibitors of calcium phosphate precipitation in whole urine. Miner Electrolyte Metab 1978; 1: 74.
110. Ryall RL, Harnett RM, Hibberd CM, et al. Urinary risk factors in calcium oxalate stone disease: Comparison of men and women. Br J Urol 1987; 60: 480-8.
111. Grover PK, Ryall RL Marshall VR. Calcium oxalate crystallization in urine: role of urate and glycosaminoglycans. Kidney Int 1992; 41: 149-54.
112. Hwang TIS, Preminger GM, Poindexter J, et al. Urinary glycosaminoglycans in normal subjects and patients with stones. J Urol 1988; 139: 995-7.
113. Martelli A, Marchesini B, Buli P, et al. Urinary excretion pattern of main glycosaminoglycans in stone formers and controls. In: Urolithiasis and related clinical research, proceedings of the 5th international conference on urolithiasis. Pp. 355-8. New York: Plenum Press, 1985.
114. Coe FL. Hyperuricosuric calcium oxalate nephrolithiasis. Kidney Int 1978; 13: 418-26.
115. Ettinger B. Does hyperuricosuria play a role in calcium oxalate lithiasis? J Urol 1989; 141: 738-41.
116. Brockis JG, Bowyer RC McCulloch RK. A review of possible roles of urates in calcium oxalate urolithiasis. Scand J Urol Nephrol 1980; 53: 179-82.
117. Shum DKY, Gohel MDI. Separate effects of urinary chondroitin sulphate and heparin sulphate on the crystallization of urinary calcium oxalate: Differences between stone formers and normal control subjects. Clin Sci 1993; 85: 33-9.
118. Hennequin C, Lalanne V, Daudon M, et al. A new approach to studying inhibitors of calcium oxalate crystal growth. Urol Res 1993; 21: 101-8.
119. Russell RGG, Edwards NA Hodgkinson A. Urinary pyrophosphate and urolithiasis. Lancet 1964; 1: 1446.
120. Robertson WG, Peacock M Nordin BEC. Inhibitors of the growth and aggregation of calcium oxalate crystals in vitro. Clin Chim Acta 1973; 43: 31-7.
121. Grases F, Costa-Bauza A, March JG, et al. Artificial stimulation of renal stone formation. Nephron 1993; 65: 77-81.
122. Shirane Y, Kagawa S. Scanning electron microscopic study of the effect of citrate and pyrophosphate on calcium oxalate crystal morphology. J Urol 1993; 150: 1980-3.
123. Sharma S, Vaidyanathan S, Thind SK, et al. Urinary excretion of inorganic pyrophosphate by normal subjects and patients with renal calculi in northwestern India and the effects of diclofenac sodium upon urinary excretion of pyrophosphate in stone formers. Urol Int 1992; 48: 404-8.
124. Singh DP, Teotia M, Teotia SPS, et al. Urinary pyrophosphate excretion in stone formers. Indian J Med Res 1985; 82: 341-5.
125. Schwille PO, Rumenapf G, Wolfel G, et al. Urinary pyrophosphate in patients with recurrent calcium urolithiasis and in healthy controls: a reevaluation. J Urol 1988; 140: 239-45.
126. Russell RGG, Bisaz S Fleisch H. The influence of orthophosphate on the renal handling of inorganic pyrophosphate in man and dog. Clin Sci Mol Med 1976; 51: 435-43.
127. Baumann JM, Ackermann D Affolter B. The influence of hydroxyapatite and pyrophosphate on the formation product of calcium oxalate at different pH's. Urol Res 1989; 17: 153-5.
128. Meyer JL, Bergert JH Smith LH. The epitaxially induced crystal growth of calcium oxalate by crystalline uric acid. Invest Urol 1976; 14: 115-9.
129. Gambaro G, Vincenti M, Marchini F, et al. Abnormal urate transport in erythrocytes of patients with idiopathic calcium nephrolithiasis: a possible link with hyperuricosuria. Clin Sci 1993; 85: 41-4.
130. Bernstein MJ. Consensus conference. Prevention and treatment of kidney stones. J Urol 1989; 141: 804-7.
131. Segura JW. The role of percutaneous surgery in renal and ureteral stone removal. J Urol 1989; 141: 780-1.
132. Kelley JM. Extracorporeal shock wave lithotripsy of urinary calculi. Theory, efficacy, and adverse effects. West J Med 1990; 153: 65-9.
133. Pak CYC. Role of medical prevention. J Urol 1989; 141: 798-801.
134. Uribarri J, Oh MS Carroll HJ. The first kidney stone. Ann Intern Med 1989; 111: 1006-9.
135. Lingeman JE, Woods J, Toth PD, et al. The role of lithotripsy and its side effects. J Urol 1989; 141: 793-7.
136. Williams HE, Wandzilak TR. Oxalate synthesis, transport and the hyperoxaluric syndromes. J Urol 1989; 141: 742-7.
137. Hodgkinson A, Zarembski PM. Oxalic acid metabolism in man: a review. Calc Tiss Res 1968; 2: 115-32.
138. Hagler L, Herman RH. Oxalate metabolism. Am J Clin Nutr 1973; 26: 758-65.
139. Williams HE, Smith LH. Primary hyperoxaluria. In: The metabolic basis of inherited disease. New York: McGraw-Hill Book Company, 1983.
140. Hodgkinson A. Oxalic acid in biology and medicine. London: Academic Press, 1977.
141. 13C]oxalate in primary hyperoxaluria: Evidence for the existence of more than one metabolic pathway from glycine to oxalate in man. Clin Sci 1968; 35: 325-35.
142. Liao LL, Richardson KE. The metabolism of oxalate precursors in isolated perfused rat livers. Arch Biochem Biophys 1972; 153: 438-48.
143. 14C]glyoxylate in isolated rat hepatocytes. Biochem Med 1976; 16: 277-83.
144. Rofe AM, James HM, Bais R, et al. Hepatic oxalate production: The role of hydroxypyruvate. Biochem Med Metab Biol 1986; 36: 141-50.
145. Wanders RJA, van Roermund CWT, Westra R, et al. Alanine glyoxylate aminotransferase and the urinary excretion of oxalate and glycolate in hyperoxaluria type 1 and the Zellweger syndrome. Clin Chim Acta 1987; 165: 311-9.
146. Gibbs DA, Watts RWE. The action of pyridoxine in primary hyperoxaluria. Clin Sci 1970; 38: 277-86.
147. Binder HJ. Intestinal oxalate absorption. Gastroenterology 1974; 67: 441-6.
148. Knickelbein RG, Dobbins JW. Sulphate and oxalate exchange for bicarbonate across the basolateral membrane of rabbit ileum. Am J Physiol 1990; 259: G807-13.
149. Knickelbein RG, Aronson PS Dobbins JW. Substrate and inhibitor specificity of anion exchangers on the brush border membrane of rabbit ileum. J Membr Biol 1985; 88: 199-204.
150. Freel RW, Hatch M, Earnest DL, et al. Oxalate transport across the isolated rat colon. A reexamination. Biochem Biophys Res Commun 1980; 600: 838-43.
151. Hatch M, Freel RW, Goldner AM, et al. Oxalate and chloride absorption by the rabbit colon: Sensitivity to metabolic and anion transport inhibitors. Gut 1984; 25: 232.
152. Prenen JAC, Boer P Dorhout Mees EJ. Absorption of oxalate from oxalate rich food in man. Am J Clin Nutr 1984; 40: 1007-10.
153. Zarembski PM, Hodgkinson A. The oxalic acid content of English diets. Br J Urol 1962; 16: 627-34.
154. Zarembski PM, Hodgkinson A. Some factors influencing the urinary excretion of oxalic acid in man. Clin Chim Acta 1969; 25: 1-10.
155. Baggio B, Gambaro G, Favaro S, et al. Prevalence of hyperoxaluria in idiopathic calcium oxalate kidney stone disease. Nephron 1983; 35: 11-4.
156. Fry DW, Richardson KE. Isolation and characterisation of glycolic acid dehydrogenase from human liver. Biochim Biophys Acta 1979; 567: 482-91.
157. Yanagawa M, Maeda-Nakai E, Yamakawa K, et al. The formation of oxalate from glycolate in rat and human liver. Biochim Biophys Acta 1990; 1036: 24-33.
158. Chalmers AH, Cowley DM McWhinney BC. Stability of ascorbate in urine: relevance to analyses for ascorbate and oxalate. Clin Chem 1985; 31: 1703-5.
159. Chalmers AH, Cowley DM Brown JM. A possible etiological role for ascorbate in calculi formation. Clin Chem 1986; 32: 333-6.
160. Schmidt KH, Hagmaier V, Hornig DH, et al. Urinary oxalate excretion after large intakes of ascorbic acid in man. Am J Clin Nutr 1981; 34: 305-11.
161. Atkins GL, Dean BM, Griffin WJ, et al. Quantitative aspects of ascorbic acid metabolism in man. J Biol Chem 1964; 239: 2975-80.
162. 14C in man. J Biol Chem 1958; 230: 923-30.
163. Baker EM, Saari JC Tolbert BM. Ascorbic acid metabolism in man. Am J Clin Nutr 1966; 19: 371-8.
164. Rivers JM. Safety of high-level vitamin C ingestion. Ann NY Acad Sci 1987; 498: 445-54.
165. Butz M, Kaiser M Fitzner R. Enhancement of urinary oxalate excretion by vitamin C - fact or artifact? In: Urolithiasis, proceedings of the 7th international conference on urolithiasis. Pp. 133-5. New York: Plenum Press, 1984.
166. Kallner A, Hartmann D Hornig D. Steady-state turnover and body pool of ascorbic acid in man. Am J Clin Nutr 1979; 32: 530-9.
167. Banay M, Dimant E. On the metabolism of L-ascorbic acid in the scrbutic guinea-pig. Biochim Biophys Acta 1962; 59: 313-9.
168. 14C in the rat. J Biol Chem 1955; 216: 539-48.
169. 14C acid. Proc Soc Exp Biol Med 1962; 109: 737-41.
170. 14C]glyoxylate in the hepatectomized rat. Biochim Biophys Acta 1983; 757: 8-14.
171. Takiguchi H, Furuyama S Shimazono N. Urinary oxalic excretion by man following ingestion of large amounts of ascorbic acid. J Vitaminol 1966; 12: 307-12.
172. Tiselius HG, Almgard LE. The diurnal urinary excretion of oxalate and the effect of pyridoxine and ascorbate on oxalate excretion. Eur Urol 1977; 3: 14-46.
173. Lamden MP, Chrystowski GA. Urinary oxalate excretion by man following ascorbic acid ingestion. Proc Soc Exp Biol Med 1954; 85: 190-2.
174. Takenouchi K, Aso K, Kawase K, et al. On the metabolites of ascorbic acid, especially oxalic acid, eliminated in urine following the administration of large amounts of ascorbic acid. J Vitaminol 1966; 12: 49-58.
175. Wandzilak TR, D'Andre SD, Davis PA, et al. Effect of high-dose vitamin C on urinary oxalate levels. J Urol 1994; 151: 834-7.
176. Singh PP, Kiran R, Pendse AK, et al. Ascorbic acid is an abettor in calcium urolithiasis: an experimental study. Scanning Microsc 1993; 7: 1041-8.
177. Bais R, Rofe AM Conyers RAJ. Inhibition of endogenous oxalate production: biochemical consideration of the role of glycolate oxidase and lactate dehydrogenase. Clin Sci 1989; 76: 303-9.
178. Romano M, Cerra M. The action of crystalline lactate dehydrogenase from rabbit on glyoxylate. Biochim Biophys Acta 1969; 177: 421-6.
179. Gibbs DA, Watts RWE. An investigation of the possible role of xanthine oxidase in the oxidation of glycolate to oxalate. Clin Sci 1966; 31: 285-97.
180. Gibbs DA, Watts RWE. The identification of the enzymes that catalyse the oxidation of glyoxylate to oxalate in the 100000 g supernatant fraction of human hyperoxaluric and control liver and heart tissue. Clin Sci 1973; 44: 227-41.
181. Warren WA. Catalysis of both oxidation and reduction of glyoxylate by pig heart lactate dehydrogenase isoenzyme 1. J Biol Chem 1970; 245: 1675-81.
182. Schuman M, Massey V. Purification and characterisation of glycolic acid oxidase from pig liver. Biochim Biophys Acta 1971; 227: 500-20.
183. Tateishi N, Higashi T, Naruse A, et al. Rat liver glutathione: possible role as a reservoir of cysteine. J Nutr 1977; 107: 51-60.
184. Asker H, Davies D. Purification of rat liver enzymes involved in the oxidation of glyoxylate. Biochim Biophys Acta 1983; 761: 103-8.
185. Gibbs DA, Hauschildt S Watts RWE. Glyoxylate oxidation in rat liver and kidney. J Biochem 1977; 82: 221-30.
186. Rofe AM, Edwards JB. Oxalate synthesis in isolated rat hepatocytes: the effects of hydroxypyruvate and amino-oxyacetate. Biochem Med 1978; 20: 323-35.
187. Smith LHJ, Bauer RL Williams HE. Oxalate and glycolate synthesis by hemic cells. J Lab Clin Med 1971; 78: 245-54.
188. Williamson DH, Lund P Krebs HA. The redox state of free nicotinamide-adenine dinucleotide in the cytoplasm and mitochondria of rat liver. Biochem J 1967; 103: 514-27.
189. Richardson KE, Tolbert NE. Oxidation of glyoxylic acid to oxalic acid by glycolic acid oxidase. J Biol Chem 1961; 236: 1280-4.
190. Liao LL, Richardson KE. The inhibition of oxalate biosynthesis in isolated perfused rat liver by DL-phenyllactate and n-heptanoate. Arch Biochem Biophys 1973; 154: 68-75.
191. Gambardella RL, Richardson KE. The formation of oxalate from hydroxypyruvate, serine, glycolate and glyoxylate in the rat. Biochim Biophys Acta 1978; 544: 315-28.
192. Richardson KE. Effect of testosterone on the glycolic acid oxidase levels in male and female rat liver. Endocrinology 1964; 74: 128-32.
193. Richardson KE. Endogenous oxalate synthesis in male and female rats. Toxicol Appl Pharmacol 1965; 7: 507-15.
194. Silbergeld S, Carter HE. Toxicity of glycolic acid in male and female rats. Arch Biochem Biophys 1959; 84: 183-7.
195. Liao LL, Richardson KE. The synthesis of oxalate from hydroxypyruvate by isolated perfused rat livers. The mechanism of hyperoxaluria in L-glyceric aciduria. Biochim Biophys Acta 1978; 538: 76-86.
196. Baker PW, Bais R Rofe AM. Formation of the (L)-cysteine-glyoxylate adduct is the mechanism by which (L)-cysteine reduces oxalate production from glycolate. Biochem J 1994; 302: 753-757.
197. Cook DA, Henderson LM. The formation of oxalic acid from the side chain of aromatic amino acids in the rat. Biochim Biophys Acta 1969; 184: 404-11.
198. 6 deficiency and hepatectomy on the synthesis of oxalate from glycolate in the rat. Biochim Biophys Acta 1983; 757: 1-7.
199. Weinhouse S, Friedmann B. Metabolism of labeled 2-carbon acids in the intact rat. J Biol Chem 1951; 191: 707-17.
200. Thompson JS, Richardson KE. Isolation and characterization of an L-alanine:glyoxylate aminotransferase from human liver. J Biol Chem 1967; 242: 3614-9.
201. Neims AH, Hellermann L. Specificity of the D-amino acid oxidase in relation to glycine oxidase activity. J Biol Chem 1962; 237: PC976.
202. Ratner S, Nocito V Green DE. Glycine oxidase. J Biol Chem 1944; 152: 119-25.
203. Cammarata PS, Cohen PP. The scope of the transamination reaction in animal tissues. J Biol Chem 1950; 187: 439.
204. Metzler DE, Olivard J Snell EE. Transamination of pyridoxamine and amino acids with glyoxylic acid. J Am Chem Soc 1957; 76: 644-9.
205. Crawhill JC. Conversion of glycine to oxalate in a normal subject. Lancet 1959; 2: 810.
206. Maxwell ES, Topper YJ. Steroid-sensitive aldehyde dehydrogenase from rabbit liver. J Biol Chem 1961; 236: 1032-7.
207. Weinhouse S. The synthesis and degradation of glycine. In: Symposium on amino acid metabolism: McCollum Pratt Institute contribution no. 105. Baltimore: The Johns Hopkins Press, 1955.
208. Noguchi T, Takada Y. Peroxisomal localization of alanine:glyoxylate aminotransferase in human liver. Arch Biochem Biophys 1979; 196: 645-7.
209. Noguchi T, Okuno E, Takada Y, et al. Characteristics of hepatic alanine-glyoxylate aminotransferase in different mammalian species. Biochem J 1978; 169: 113-22.
210. Rowsell EV, Snell K, Carnie JA, et al. The subcellular distribution of rat liver L-alanine-glyoxylate aminotransferase in relation to a pathway for glucose formation involving glyoxylate. Biochem J 1972; 127: 155-65.
211. 6 deficiency on oxalate metabolism in male rats. Ann Nutr Metab 1990; 34: 104-11.
212. Danpure CJ, Jennings PR. Further studies on the activity and subcellular distribution of alanine:glyoxylate aminotransferase in the livers of patients with primary hyperoxaluria type 1. Clin Sci 1988; 75: 315-22.
213. Purdue PE, Allsop J, Isaya G, et al. Mistargeting of peroxisomal
214. O'Fallon JV, Brosemer RW. Cellular localization of α-ketoglutarate:glyoxylate carboligase in rat tissues. Biochim. Biophys Acta 1977; 499: 321-8.
215. Stewart CB, Grammer J Brosemer RW. Thiamine deficiency and glyoxylic acid. Ann Nutr Metab 1981; 25: 289-98.
216. Chow FC, Hamar DW, Boulay JP, et al. Prevention of oxalate urolithiasis by some compounds. Invest Urol 1978; 15: 493-5.
217. Rooney CS, Randall WC, Streeter KB, et al. Inhibitors of glycolic acid oxidase. 4-Substituted 3-hydroxy-1-H-pyrrole-2,5-dione derivatives. J Med Chem 1983; 26: 700-14.
218. Zinsser HH, Karp F. How to diminish endogenous oxalate excretion. Invest Urol 1973; 10: 249-52.
219. Talware HS, Madiraju VS, Murthy SR, et al. Preliminary report. Normalization of urinary oxalate by taurine in glycolate-fed rats. Metabolism 1985; 34: 97-100.
220. Sharma V, Thind SK Nath R. Effect of sex hormones and glycollate feeding on rat liver glycollate oxidase. Urol Res 1984; 12: 76-80.
221. O'Keeffe CM, Cies L Smith LH. Inhibition of oxalate biosynthesis: In vivo studies in the rat. Biochem Med 1973; 7: 299-307.
222. Selvam GS, Varalakshmi P. Effect of different isomers of tartrate on oxalate metabolism in hyperoxaluric rats. Med Sci Res 1989; 17: 685-7.
223. Selvam GS, Varalakshmi P. Role of L(+)-tartrate in experimental calcium oxalate urolithiasis. Med Sci Res 1990; 18: 313-5.
224. Bais R, Rofe AM Conyers RAJ. The inhibition of metabolic oxalate production by sulphydryl compounds. J Urol 1991; 145: 1302-5.
225. Baker PW, Bais R Rofe AM. The efficacy of (L)-2-oxothiazolidine-4-carboxylate (OTC) and (L)-cysteine in reducing urinary oxalate excretion. J Urol November 1994 (in press).
226. Sharma V, Schwille PO. Oxalate production form glyoxylate by lactate dehydrogenase in vitro: Inhibition by reduced glutathione, cysteine and cysteamine. Biochem Int 1992; 27: 431-8.
227. Sharma V. Schwille PO. Sulphite inhibits oxalate production from glycolate and glyoxylate in vitro and from dichloroacetate infused IV into male rats. Biochem Med Metab Biol 1993; 49: 265-9.
228. Schubert MP. Reactions of semimercaptals with amino compounds. J Biol Chem 1936; 121: 539-48.
229. Schmolka IR, Spoerri PE. Thiazolidine chemistry. II. The preparation of 2-substituted thiazolidine-4-carboxylic acids. Org Chem 1957; 22: 943-6.
230. Ratner S, Clarke HT. The action of formaldehyde upon cysteine. J Am Chem Soc 1937; 59: 200-6.
231. Burns CL, Main DE, Buckthal DJ, et al. Thiazolidine-2-carboxylate derivatives formed from glyoxylate and L-cysteinylglycine as possible physiological substrates for D-aspartate oxidase. Biochem Biophys Res Commun 1984; 125: 1039-45.
232. Hamilton GA. Peroxisomal oxidases and suggestions for the mechanism of action of insulin and other hormones. Adv Enzymol 1985; 57: 85-178.
233. Venkatesan PP, Hamilton GA. The nonenzymatic hydrolysis of thiazolidine-2-carboxylate: the product of the suspected physiological reaction catalyzed by D-amino acid oxidase. Bioorg Chem 1986; 14: 392-404.
234. Pesek JJ, Frost JH. Decomposition of thiazolidines in acidic and basic solution. Tetrahedron 1975; 31: 907-13.
235. Skorczynski SS, Hamilton GA. Oxalyl thioesters and N-oxalylcysteine are normal mammalian metabolites. Biochem Biophys Res Commun 1986; 141: 1051-7.
236. Alary J, Carrera G, De Saint Blanquat G, et al. Reversed-phase ion-pair high-performance liquid chromatographic determination of 2-carboxythiazolidine-4-carboxylic acid in plasma. J Chromatogr 1989; 496: 485-92.
237. Lamboeuf Y, De Saint Blanquat G, Roumec C, et al. Impairment of mitochondrial membrane by ethanol and protective effect of a thiazolidine compound in in vitro and in vivo experiments. Food Additive Contam 1990; 7: S138-41.
238. Saigot T. Interet du tiadilon en pathologie hepatobiliaire. MCD 1979; 8: 575-6.
239. Raymond N. Interet de l'utilisation en gastro-enterologie d'un hepatotrope original, le tidiacicate d'arginine. MCD 1981; 10: 181-4.
240. Parkinson IS, Channon SM, Tomson CRV, et al. The determination of plasma oxalate concentrations using an enzyme/bioluminescent assay. II. Co-immobilisation of bioluminescent enzymes and studies of in vitro oxalogenesis. Clin Chim Acta 1989; 179: 97-108.
241. Schwille PO, Manoharan M, Rumenapf G, et al. Oxalate measurement in the picomole range by ion chromatography: Values in fasting plasma and urine of controls and patients with idiopathic calcium urolithiasis. J Clin Chem Clin Biochem 1989; 27: 87-96.
242. Crider QE, Curran DF. Simplified method for enzymatic urine oxalate assay. Clin Biochem 1984; 17: 351-5.
243. Wilson DM, Liedtke RR. Modified enzyme based colourimetric assay of urinary and plasma oxalate with improved sensitivity and no ascorbate interference: reference values and sample handling procedures. Clin Chem 1991; 37: 1229-35.
244. Munoz Leyva JA, Hernandez Artiga MP, Aragon Mendez MM, et al. Atomic absorption and UV-VIS absorption spectrophotometric determination of oxalate in urine by ligand exchange extraction. Clin Chim Acta 1990; 195: 47-56.
245. Berckmans RJ, Boer P. An inexpensive method for sensitive enzymatic determination of oxalate in urine and plasma. Clin Chem 1988; 34: 1451-5.
246. Coyle PC, Rofe AM Renfeng F. Improved urinary oxalate method for a centrifugal analyser. Clin Chem 1989; 35: 1806.
247. Potezny N, Bais R, O'Loughlin PD, et al. Urinary oxalate determination by use of immobilized oxalate oxidase in a continuous-flow system. Clin Chem 1983; 29: 827-30.
248. Fry IDR, Starkey BJ. The determination of oxalate in urine and plasma by high performance liquid chromatography. Ann Clin Biochem 1991; 28: 581-7.
249. Goldsack K, Ginman RFA Wright JM. Direct determination of urinary oxalate by a continuous flow method. Med Lab Sci 1990; 47: 73-9.
250. Li MG, Madappally MM. Rapid enzymatic determination of urinary oxalate. Clin Chem 1989; 35: 2330-3.
251. Sharma S, Nath R Thind SK. Recent advances in measurement of oxalate in biological materials. Scanning Microsc 1993; 7: 431-41.
252. Costello J, Landwehr DM. Determination of oxalate concentration in blood. Clin Chem 1988; 34: 1540-4.
253. Hatch M, Bourke E Costello J. New enzymatic method for serum oxalate determination. Clin Chem 1977; 23: 76-8.
254. Hatch M. Spectrophotometric determination of oxalate in whole blood. Clin Chim Acta 1990; 193: 199-202.
255. Allen LC, Kadijevic L Romaschin AD. An enzymatic method for oxalate automated with the cobas fara centrifugal analyzer. Clin Chem 1989; 35: 2098-100.
256. Laker MF, Hofmann AF Meeuse BJD. Spectrophotometric determination of urinary oxalate with oxalate oxidase prepared from moss. Clin Chem 1980; 26: 827-30.
257. Strauss E, Meerkins M, Moshides J. Convenient urine oxalate assay with an oxalate oxidase reagent and a centrifugal analyzer. Clin Chem 1987; 33: 2301.
258. Arrington CJ, Chalmers AH. Gas chromatographic estimation of urinary oxalate and its comparison with a colorimetric method. Clin Chem 1979; 25: 1993-6.
259. Yanagawa M, Ohkawa H Tada S. The determination of urinary oxalate by gas chromatography. J Urol 1983; 129: 1163-5.
260. Schwendtner N, Achilles W, Engelhardt W, et al. Determination of urinary oxalate by isotachophoresis, practical improvement and critical evaluation. J Clin Chem Clin Biochem 1982; 20: 833-6.
261. Tschope W, Ritz E. Isotachophoretic determination of oxalate in unprocessed urine. In: Smith LH, Robertson WG, Findlayson B (eds). Urolithiasis, clinical and basic research. Pp. 951-75. New York: Plenum Press, 1981.
262. Lopez M, Tuchman M Scheinman JI. Capillary gas chromatography measurement of oxalate in plasma and urine. Kidney Int 1985; 28: 82-4.
263. Pal Singh RAJ, Nancollas GH. Determination of phosphate, sulfate and oxalate in urine by ion chromatography. J Chromatogr 1988; 433: 373-6.
264. Prenen JAC, Peter BL. Urinary oxalate excretion determined by isotope dilution and indirect colorimetry. Clin Chim Acta 1983; 127: 251-61.
265. France NC, Holland PT, McGhie TK, et al. Measurement of plasma oxalate by capillary gas chromatography and its validation by isotope dilution mass spectrometry. J Chromatogr 1988; 433: 1-7.
266. Hagen L, Walker VR Sutton RAL. Plasma and urinary oxalate and glycolate in healthy subjects. Clin Chem 1993; 39: 134-8.
267. Wandzilak TR, D'Andre SD, Davis PA, et al. Effect of high dose vitamin C on urinary oxalate levels. J Urol 1994; 151: 834-7.
268. Larsson L, Libert B Asperud M. Determination of urinary oxalate by reversed-phase ion-pair high performance liquid chromatography. Clin Chem 1982; 28: 2212-4.
269. Wildman BJ, Jackson PE, Jones WR, et al. Analysis of anion constituents of urine by inorganic capillary electrophoresis. J Chromatogr 1991; 546: 459-66.
270. Huggins TG, Henion JD. Capillary electrophoresis/mass spectrometry determination of inorganic ions spray-sheath flow interface. Electrophoresis 1993; 14: 531-9.
271. Hornig DH, Moser U. The safety of high vitamin C intakes in man. In: Vitamin C (ascorbic acid). London: Applied Science Publishers, 1981.
272. Herbert V. The antioxidant supplement myth. Am J Clin Nutr 1994; 60: 157-8.
273. Inamdar KV, Raghavan KG Pradhan DS. Five treatment procedures evaluated for the elimination of ascorbate interference in the enzymatic determination of urinary oxalate. Clin Chem 1991; 37: 864-8.
274. Petrarulo M, Marangella M, Bianco O, et al. Preventing ascorbate interference in ion-chromatographic determinations of urinary oxalate: four methods compared. Clin Chem 1990; 36: 1642-5.